cAMP Hunter™ Tirzepatide (GIP RA) Bioassay Kit
The cAMP Hunter™ Tirzepatide (GIP RA) Bioassay kit provides an easy-to-use cell based assay to measure drug potency and detect neutralizing antibodies. This bioassay is a robust, sensitive cell-based assay that monitors cAMP production in response to Tirzepatide-induced GIP receptor activation.
Catalog #: 95-0146Y2-00209
Size:
10-Plate No Control
Unit Price: USD 9,779.00
Log in to see your actual price
Qty
Overview
Specifications
Documentation
Resources
Related Info
Biological Background
The Gastric Inhibitory Polypeptide Receptor (GIPR) is a class B GPCR located on pancreatic β-cells, adipose tissue, and the gastrointestinal tract, where GIP binding stimulates Gαs coupling, adenylyl cyclase activation, and cAMP production. This cascade enhances glucose-dependent insulin secretion, modulates lipid metabolism, and regulates energy balance. As part of the incretin pathways alongside GLP-1, GIPR agonists like tirzepatide highlight the therapeutic importance of dual-incretin modulation in metabolic and obesity research.
This bioassay kit supports pharmaceutical development of GIPR-targeted therapies for diabetes, obesity, and metabolic disorders. Use cases include drug characterization, lot release testing, stability studies, and neutralizing antibody screening. Its ready-to-use format accelerates assay setup and delivers reproducible results across laboratories.
The qualified cAMP Hunter™ Tirzepatide (GIP RA) Bioassay Kit features qualified CHO-K1 cells overexpressing human GIPR, EFC-based cAMP detection reagents, cell plating media, dilution buffer, control agonist (optional), and 96-well plates.
Product Highlights
- Optimized and qualified with tirzepatide, ensuring accurate potency measurement and neutralizing antibody detection
- Ready-to-use cryopreserved CHO-K1 GIPR cells, detection reagents, cell plating media, dilution buffer, control agonist, and 96-well plates (control agonist optional format)
- Qualified bioassay with comprehensive validation: 104.9% average recovery, 11.4% RSD intermediate precision, and R2 = 0.9998 linearity
- Robust plate uniformity (8.0% CV), inter-row/inter-column CV < 5%, and day-to-day repeatability (RSD < 22.9%)
- Demonstrated dilutional linearity (50–200% nominal range) and inter-analyst reproducibility
cAMP Hunter Tirzepatide GIP RA Assay Principle
In the cAMP Hunter™ Tirzepatide (GIP RA) Bioassay, CHO-K1 cells overexpress human GIPR to monitor receptor activation via native Gαs coupling. Ligand binding stimulates adenylate cyclase to convert ATP to cAMP. Intracellular cAMP competes with ED-labeled cAMP for anti-cAMP antibody in a homogeneous, gain-of-signal EFC assay. Unbound ED-cAMP complements with EA fragment to form active β-gal, which cleaves substrate to generate chemiluminescence proportional to cellular cAMP.
cAMP Hunter Tirzepatide GIP RA Qualification Data
The qualification of the cAMP Hunter™ Tirzepatide (GIP RA) Bioassay Kit confirms its strong performance and reliability for QC lot release, drug characterization, and biosimilar assessment. Comprehensive studies demonstrated excellent accuracy (average recovery 104.9%), repeatability (12.4% RSD), and intermediate precision (11.4% RSD), with superior dilutional linearity (R2 = 0.9998) across the 50–200% potency range.
The kit consistently produced robust and uniform results across plate positions, different analysts, and multiple cell lots. To see detailed data and explore how this bioassay can support your product development or QC workflow, download the full qualification report.
View qualification data